Evolve Biologics
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Open-label Multicenter Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Hepatocellular Carcinoma (NCT03908840) | Evolve Biologics | 2019-12-01 |
| Study of PlasmaCap IG in Adults and Children With PIDD (NCT03238079) | Evolve Biologics | 2017-09-05 |
Track Evolve Biologics automatically
Every clearance here is in the API, with alerts when new ones post.